Skip to content
Peptigraph home

TB-500 Dosage: Doses Studied, Units and Chart

What doses of TB-500 have been used in published research, how they convert to syringe units, and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureSynthetic fragment of thymosin beta-4Updated
Doses studied
11 studies
with a stated dose, listed below
Frequency
Varies by study
as used in studies
Half-life
Not found
No published half-life found (PubMed search, 2 Oct 2026)
Vial sizes sold
2 mg, 5 mg, 10 mg, 20 mg

Doses used in published studies

Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.

Doses of TB-500 used in published studies
DoseFrequency and routeStudy typeSource
0.05 to 25.0 ug/kg single; 0.5, 2.0 and 5.0 ug/kg dailysingle dose or once daily · intravenous · 10 days (multiple-dose cohorts)Human RCTJournal of cellular and molecular medicine 2021, PMID 34346165
0.5 mg/ml geltopical (scalp) · 4 weeksHuman controlled trialn = 71Microbial biotechnology 2021, PMID 34318587
0.1%6 times daily · eye drops · 28 daysHuman RCTn = 9Cornea 2015, PMID 25826322
0.1%eye drops · 28 daysHuman RCTn = 72Clinical ophthalmology 2015, PMID 26056426
42, 140, 420 or 1260 (mg, as stated in abstract)single dose, then daily · intravenous · 14 daysHuman RCTn = 40Annals of the New York Academy of Sciences 2010, PMID 20536472
topical, 0.03% dose highlightedtopicalHuman RCTn = 73Annals of the New York Academy of Sciences 2010, PMID 20536470
TB-500 60 ug/kg/day; BPC-157 10 ug/kg/daydaily · intraperitoneal · four weeksAnimal · rat (not a human result)n = 32Joint diseases and related surgery 2026, PMID 42542926
2, 12 or 18 mg/kg24 h after stroke then every 3 days for 4 additional doses · intraperitonealAnimal · rat (not a human result)n = 10Journal of the neurological sciences 2014, PMID 25060418
1 ug in 100 uL fibrin sealantsingle placement at surgery · local, in the ligament gapAnimal · rat (not a human result)Regulatory peptides 2013, PMID 23523891
10 mg N-acetylated LKKTETQsingle doseAnimal · horse (not a human result)Journal of chromatography. A 2012, PMID 23084823
400 microgramsintraperitonealAnimal · mouse (not a human result)International journal of immunopharmacology 1997, PMID 9226473

Dose to syringe units

For a 10 mg vial mixed with 2 mL of bacteriostatic water (5 mg/mL), on a U-100 syringe. These are reference amounts for the math, not suggested doses.

0.5 mg
10 u
1 mg
20 u
2 mg
40 u
2.5 mg
50 u
5 mg
100 u
Use your own vial and water

Before anyone considers it

  • TB-500 is not FDA approved for any use.
  • Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
  • Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
  • People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.

Common questions

How many units is 2 mg of TB-500?

It depends on the water added. A 10 mg vial with 2 mL of water gives 5 mg/mL, so 2 mg is 40 units on a U-100 syringe. Use the calculator for other mixes.

Is TB-500 FDA approved?

No. TB-500 is not FDA approved for any use. The FDA removed it from Category 2 on 15 Apr 2026. Its advisory committee voted 8–6 in July 2026 to add it to the 503A compounding list. That vote is not final.

More on TB-500

Side effectsWhat labels and studies report, and what is unknown.CalculatorVial, water and dose to syringe units.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.How to injectSites, syringe types and hygiene, step by step.

Sources

  1. 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  2. 2Pharmacy Compounding Advisory Committee meeting, 23–24 Jul 2026 (agenda and materials)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  3. 3Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  4. 4BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  5. 5A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.Journal of cellular and molecular medicine · 2021PMID 34346165Accessed 2 Oct 2026
  6. 6Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.Microbial biotechnology · 2021PMID 34318587Accessed 2 Oct 2026
  7. 7Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.Cornea · 2015PMID 25826322Accessed 2 Oct 2026
  8. 8Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.Clinical ophthalmology (Auckland, N.Z.) · 2015PMID 26056426Accessed 2 Oct 2026
  9. 9A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.Annals of the New York Academy of Sciences · 2010PMID 20536472Accessed 2 Oct 2026
  10. 10The effect of thymosin treatment of venous ulcers.Annals of the New York Academy of Sciences · 2010PMID 20536470Accessed 2 Oct 2026
  11. 11Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
  12. 12A dose-response study of thymosin β4 for the treatment of acute stroke.Journal of the neurological sciences · 2014PMID 25060418Accessed 2 Oct 2026
  13. 13Thymosin β4 enhances the healing of medial collateral ligament injury in rat.Regulatory peptides · 2013PMID 23523891Accessed 2 Oct 2026
  14. 14Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.Journal of chromatography. A · 2012PMID 23084823Accessed 2 Oct 2026
  15. 15Biodistribution of synthetic thymosin beta 4 in the serum, urine, and major organs of mice.International journal of immunopharmacology · 1997PMID 9226473Accessed 2 Oct 2026
  16. 16PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) (1199 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (humans[mh] OR patients[tiab]) (678 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  18. 18PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (randomized[tiab] OR clinical trial[pt]) (18 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  19. 19PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  20. 20PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (wound[tiab] OR dermal[tiab] OR skin[tiab] OR hair[tiab]) (212 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  21. 21PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (tendon[tiab] OR muscle[tiab] OR cardiac[tiab] OR myocardial[tiab] OR heart[tiab]) (246 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  22. 22PubMed search: "TB-500"[tiab] OR TB500[tiab] OR "Ac-LKKTETQ"[tiab] (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.